You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEK

Showing 1 - 25 of 543
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma (Skin), Skin Cancer, Skin Melanoma Trial in Tampa (Vemurafenib, Cobimetinib)

Recruiting
  • Melanoma (Skin)
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022

Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma Trial in Leiden (Encorafenib + Binimetinib)

Recruiting
  • Melanoma Stage III
  • In-Transit Metastasis of Cutaneous Melanoma
  • Encorafenib + Binimetinib
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Mar 2, 2023

Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 14, 2022

Arteriovenous Malformations Trial (Trametinib tablet)

Not yet recruiting
  • Arteriovenous Malformations
  • Trametinib tablet
  • (no location specified)
Oct 17, 2023

Gastrointestinal Stromal Tumor (GIST) Trial in New York (drug, other, procedure)

Active, not recruiting
  • Gastrointestinal Stromal Tumor (GIST)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 28, 2022

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

Healthy Trial in Neu-Ulm (ATR-002, Placebo, Repaglinide)

Recruiting
  • Healthy
  • Neu-Ulm, Germany
    Atriva study site
Sep 22, 2022

NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Phase I - Mirdametinib - Level 1
  • +4 more
  • (no location specified)
Jul 7, 2023

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • New York, New York
  • +2 more
Jun 28, 2022

Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

Active, not recruiting
  • Gastrointestinal Cancer
  • New York, New York
  • +1 more
Nov 29, 2022

Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD) Trial (Mirdametinib)

Not yet recruiting
  • Langerhans Cell Histiocytosis (LCH)
  • +3 more
  • (no location specified)
Nov 22, 2023

Pancreatic Ductal Adenocarcinoma Trial in Miami (Trametinib, Ruxolitinib, Retifanlimab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Miami, Florida
    University of Miami
Jun 27, 2022

Lung Cancer Trial in Boston (Binimetinib, Palbociclib)

Recruiting
  • Lung Cancer
  • Boston, Massachusetts
  • +1 more
Jan 18, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
  • +2 more
Jun 14, 2022

Prostate Cancer Trial in Los Angeles (degarelix, enzalutamide, trametinib)

Active, not recruiting
  • Prostate Cancer
  • Los Angeles, California
    University of California, Los Angeles
Aug 25, 2022

Low-Grade Gliomas, Malignant Tumors, Brain, Soft Tissue Tumors Trial in United States (MEK162)

Active, not recruiting
  • Low-Grade Gliomas
  • +2 more
  • Birmingham, Alabama
  • +14 more
Jan 25, 2023

Rechallenge of BRAF +/- MEK Inhibitors FollowingAdverse Event in

Active, not recruiting
  • Cancer
  • BRAF inhibitor
  • (no location specified)
Oct 13, 2021

Gastric Cancer, Metaplasia, Stage I Gastric Cancer Trial in Tokyo (Trametinib treatment, Endoscopy)

Not yet recruiting
  • Gastric Cancer
  • +3 more
  • Trametinib treatment
  • Endoscopy
  • Tokyo, Japan
  • +1 more
Feb 12, 2022

Non Small Cell Lung Cancer Trial in Shanghai (Trametinib, Anlotinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Jan 16, 2022

Acute Malnutrition in Childhood Trial in Mek'ele (Bahgina, SQLNS)

Recruiting
  • Acute Malnutrition in Childhood
  • Bahgina
  • SQLNS
  • Mek'ele, Tigray, Ethiopia
    Tigray Health Research Institute
Oct 22, 2023

Sarcoma,Soft Tissue Trial in France (Cobimetinib, Atezolizumab)

Recruiting
  • Sarcoma,Soft Tissue
  • Angers, France
  • +4 more
Mar 28, 2022

Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma Trial in Memphis (Mirdametinib)

Recruiting
  • Low-Grade Glioma
  • +2 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 24, 2022

Digestive System Tumors Trial in Zhengzhou (a CDK4 / 6 inhibitor and a MEK inhibitor)

Recruiting
  • Digestive System Tumors
  • a CDK4 / 6 inhibitor and a MEK inhibitor
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 20, 2021